Compare MFIC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | EVO |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 907.7M | 934.1M |
| IPO Year | N/A | N/A |
| Metric | MFIC | EVO |
|---|---|---|
| Price | $10.67 | $2.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $11.25 | $7.00 |
| AVG Volume (30 Days) | ★ 572.6K | 91.4K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | $10.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.48 | $2.31 |
| 52 Week High | $13.51 | $4.80 |
| Indicator | MFIC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 46.32 |
| Support Level | $10.01 | $2.63 |
| Resistance Level | $11.81 | $3.78 |
| Average True Range (ATR) | 0.29 | 0.09 |
| MACD | -0.14 | -0.04 |
| Stochastic Oscillator | 14.04 | 33.38 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. The investment objective of the company is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.